Tumour and germline molecular profiling for Biliary Tract Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Biliary Tract CancerTumour and germline molecular profiling - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is investigating the feasibility of returning whole genome sequencing results within 8 weeks of a biliary tract cancer tumor biopsy, in order to identify actionable molecular alterations that may improve clinical outcomes.

Eligible Conditions
  • Biliary Tract Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CTX-009 plus Paclitaxel
1
XmAb20717
1
Cisplatin

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 4 years

2 years
Number of participants with tumour whole genome sequencing returned within 8 weeks
4 years
Disease control rate
Number of patients in whom at least 1 actionable mutation is identified
Therapeutic procedure
Overall survival rate
Progression-free survival rate

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
CTX-009 plus Paclitaxel
2
XmAb20717
1
Cisplatin

Trial Design

1 Treatment Group

Individuals with advanced biliary tract cancer
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Tumour and germline molecular profiling · No Placebo Group · N/A

Individuals with advanced biliary tract cancer
Other
Experimental Group · 1 Intervention: Tumour and germline molecular profiling · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
399 Previous Clinical Trials
125,482 Total Patients Enrolled
Cancer Research SocietyUNKNOWN

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are fit to undergo a tumour biopsy as judged by the investigator.
Patients must have a measurable lesion by RECIST 1.
You have a life expectancy of greater than 90 days.
You are able to understand and willing to sign a written informed consent document.
You have a histological or radiological diagnosis of inoperable or metastatic BTC.
You have a tumour that is amenable to a core needle biopsy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top